Efficacy of Peg-interferon α-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss

• Status: Unknown status
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

For HBeAg (+) hepatitis B patients who have been treated by entecavir for 48 weeks but without HBeAg loss, switching to peg-interferon may increase the response rate. In the investigators study, patients were divided into two groups. In Group A, patients continued entecavir for another 72 weeks. In Group B, patients switched to peg-interferon-2a monotherapy for 48 weeks, then followed up 24 weeks.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Entecavir; Interferon-alpha; Interferons; Peginterferon alfa-2a

Criteria

Inclusion Criteria:

• Age between 18 and 50 years old

• HBsAg(+) and HBeAg(+) for over 6 months before entecavir treatment

• Treated by entacavir for 48 weeks with HBeAg seroconversion

Exclusion Criteria:

• Pregnant women

• Decompensated liver disease

• Combination infection of HCV, HAV, or HEV

• Combination infection of HIV

• Any contraindication of interferon α